| Patient Population | Pharmacotherapies | ||
|---|---|---|---|
| Medications that reduce overall fracture risk in the given patient populations: | |||
| Patients with high risk for fracture (including postmenopausal women with osteoporosis) | Alendronate | Risedronate |
 |
| Denosumab | Teriparatide | ||
| Ibandronate | Zoledronic acid | ||
| Raloxifene | |||
| Patients treated with glucocorticoids | Alendronate | Teriparatide |
 to
|
| Risedronate | |||
| Patients with a higher risk of falling (e.g., patients with hemiplegia, Alzheimer’s disease, or Parkinson’s disease) | Alendronate | Vitamin D |
|
| Risedronate | |||
| Transplant recipients and patients treated chronically with corticosteroids | Inconclusive support for any agents |
 | |
| Medications that reduce fragility fracture risk in the given patient populations: | |||
| Postmenopausal women with osteopenia who do not have prevalent vertebral fractures | Risedronate |
 to
| |
From: Treatment To Prevent Osteoporotic Fractures: An Update
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.